- Canada
- /
- Healthcare Services
- /
- TSX:QIPT
Calculating The Fair Value Of Quipt Home Medical Corp. (TSE:QIPT)
Key Insights
- Quipt Home Medical's estimated fair value is CA$7.63 based on 2 Stage Free Cash Flow to Equity
- Current share price of CA$8.05 suggests Quipt Home Medical is potentially trading close to its fair value
- Our fair value estimate is 44% lower than Quipt Home Medical's analyst price target of US$13.63
How far off is Quipt Home Medical Corp. (TSE:QIPT) from its intrinsic value? Using the most recent financial data, we'll take a look at whether the stock is fairly priced by taking the expected future cash flows and discounting them to today's value. We will use the Discounted Cash Flow (DCF) model on this occasion. There's really not all that much to it, even though it might appear quite complex.
We would caution that there are many ways of valuing a company and, like the DCF, each technique has advantages and disadvantages in certain scenarios. For those who are keen learners of equity analysis, the Simply Wall St analysis model here may be something of interest to you.
See our latest analysis for Quipt Home Medical
The Calculation
We are going to use a two-stage DCF model, which, as the name states, takes into account two stages of growth. The first stage is generally a higher growth period which levels off heading towards the terminal value, captured in the second 'steady growth' period. In the first stage we need to estimate the cash flows to the business over the next ten years. Where possible we use analyst estimates, but when these aren't available we extrapolate the previous free cash flow (FCF) from the last estimate or reported value. We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. We do this to reflect that growth tends to slow more in the early years than it does in later years.
Generally we assume that a dollar today is more valuable than a dollar in the future, so we need to discount the sum of these future cash flows to arrive at a present value estimate:
10-year free cash flow (FCF) estimate
2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | |
Levered FCF ($, Millions) | US$14.2m | US$16.4m | US$14.0m | US$12.7m | US$11.9m | US$11.5m | US$11.2m | US$11.1m | US$11.1m | US$11.2m |
Growth Rate Estimate Source | Analyst x1 | Analyst x1 | Est @ -14.55% | Est @ -9.63% | Est @ -6.18% | Est @ -3.77% | Est @ -2.08% | Est @ -0.90% | Est @ -0.07% | Est @ 0.51% |
Present Value ($, Millions) Discounted @ 6.2% | US$13.4 | US$14.6 | US$11.7 | US$10.0 | US$8.8 | US$8.0 | US$7.4 | US$6.9 | US$6.5 | US$6.1 |
("Est" = FCF growth rate estimated by Simply Wall St)
Present Value of 10-year Cash Flow (PVCF) = US$93m
The second stage is also known as Terminal Value, this is the business's cash flow after the first stage. The Gordon Growth formula is used to calculate Terminal Value at a future annual growth rate equal to the 5-year average of the 10-year government bond yield of 1.9%. We discount the terminal cash flows to today's value at a cost of equity of 6.2%.
Terminal Value (TV)= FCF2033 × (1 + g) ÷ (r – g) = US$11m× (1 + 1.9%) ÷ (6.2%– 1.9%) = US$263m
Present Value of Terminal Value (PVTV)= TV / (1 + r)10= US$263m÷ ( 1 + 6.2%)10= US$144m
The total value is the sum of cash flows for the next ten years plus the discounted terminal value, which results in the Total Equity Value, which in this case is US$238m. To get the intrinsic value per share, we divide this by the total number of shares outstanding. Relative to the current share price of CA$8.1, the company appears around fair value at the time of writing. Remember though, that this is just an approximate valuation, and like any complex formula - garbage in, garbage out.
The Assumptions
Now the most important inputs to a discounted cash flow are the discount rate, and of course, the actual cash flows. Part of investing is coming up with your own evaluation of a company's future performance, so try the calculation yourself and check your own assumptions. The DCF also does not consider the possible cyclicality of an industry, or a company's future capital requirements, so it does not give a full picture of a company's potential performance. Given that we are looking at Quipt Home Medical as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighted average cost of capital, WACC) which accounts for debt. In this calculation we've used 6.2%, which is based on a levered beta of 0.865. Beta is a measure of a stock's volatility, compared to the market as a whole. We get our beta from the industry average beta of globally comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business.
SWOT Analysis for Quipt Home Medical
- Debt is well covered by cash flow.
- Earnings declined over the past year.
- Interest payments on debt are not well covered.
- Shareholders have been diluted in the past year.
- Annual earnings are forecast to grow faster than the Canadian market.
- Good value based on P/S ratio compared to estimated Fair P/S ratio.
- No apparent threats visible for QIPT.
Moving On:
Although the valuation of a company is important, it is only one of many factors that you need to assess for a company. DCF models are not the be-all and end-all of investment valuation. Preferably you'd apply different cases and assumptions and see how they would impact the company's valuation. If a company grows at a different rate, or if its cost of equity or risk free rate changes sharply, the output can look very different. For Quipt Home Medical, we've compiled three important factors you should consider:
- Risks: As an example, we've found 4 warning signs for Quipt Home Medical (1 is significant!) that you need to consider before investing here.
- Future Earnings: How does QIPT's growth rate compare to its peers and the wider market? Dig deeper into the analyst consensus number for the upcoming years by interacting with our free analyst growth expectation chart.
- Other High Quality Alternatives: Do you like a good all-rounder? Explore our interactive list of high quality stocks to get an idea of what else is out there you may be missing!
PS. The Simply Wall St app conducts a discounted cash flow valuation for every stock on the TSX every day. If you want to find the calculation for other stocks just search here.
Valuation is complex, but we're here to simplify it.
Discover if Quipt Home Medical might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About TSX:QIPT
Quipt Home Medical
Through its subsidiaries, engages in the provision of durable and home medical equipment and supplies in the United States.
Undervalued with adequate balance sheet.